Among these, kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutations are prevalent in approximately 30% of NSCLC cases and represent a critical therapeutic target (10–12). This evidence concerns the gene KRAS and non-small cell lung carcinoma.